Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 128

1.

A novel assay to detect calreticulin mutations in myeloproliferative neoplasms.

Rosso V, Petiti J, Bracco E, Pedrola R, Carnuccio F, Signorino E, Carturan S, Calabrese C, Bot-Sartor G, Ronconi M, Serra A, Saglio G, Frassoni F, Cilloni D.

Oncotarget. 2016 Dec 23. doi: 10.18632/oncotarget.14113. [Epub ahead of print]

2.

Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection.

Carturan S, Petiti J, Rosso V, Calabrese C, Signorino E, Bot-Sartor G, Nicoli P, Gallo D, Bracco E, Morotti A, Panuzzo C, Gottardi E, Frassoni F, Saglio G, Cilloni D.

Oncotarget. 2016 Nov 8;7(45):74082-74096. doi: 10.18632/oncotarget.12269.

3.

The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.

Carrà G, Torti D, Crivellaro S, Panuzzo C, Taulli R, Cilloni D, Guerrasio A, Saglio G, Morotti A.

Oncotarget. 2016 Oct 4;7(40):66287-66298. doi: 10.18632/oncotarget.11507. Review.

4.

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pieri L, Fjerza R, Pietra D, Cilloni D, Sant'Antonio E, Salmoiraghi S, Passamonti F, Rambaldi A, Barosi G, Barbui T, Cazzola M, Vannucchi AM.

Am J Hematol. 2016 Sep;91(9):918-22. doi: 10.1002/ajh.24442.

PMID:
27264006
5.

The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy.

Gallo D, Nicoli P, Calabrese C, Gaidano V, Petiti J, Rosso V, Signorino E, Carturan S, Bot-Sartor G, Volpe G, Frassoni F, Saglio G, Cilloni D.

Cancer Med. 2016 Jul;5(7):1650-3. doi: 10.1002/cam4.735.

6.

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.

Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, Brogi G, Fanelli T, Pancrazzi A, Pietra D, Bernardis I, Belotti C, Pieri L, Sant'Antonio E, Salmoiraghi S, Cilloni D, Rambaldi A, Passamonti F, Barbui T, Manfredini R, Cazzola M, Tagliafico E, Vannucchi AM, Guglielmelli P.

Am J Hematol. 2016 Jul;91(7):681-6. doi: 10.1002/ajh.24377.

PMID:
27037840
7.

Clinical significance of TFR2 and EPOR expression in bone marrow cells in myelodysplastic syndromes.

Di Savino A, Gaidano V, Palmieri A, Crasto F, Volpengo A, Lorenzatti R, Scaravaglio P, Manello A, Nicoli P, Gottardi E, Saglio G, Cilloni D, De Gobbi M.

Br J Haematol. 2016 Feb 23. doi: 10.1111/bjh.13968. [Epub ahead of print] No abstract available.

PMID:
26914246
8.

MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation.

De Luca L, Trino S, Laurenzana I, Simeon V, Calice G, Raimondo S, Podestà M, Santodirocco M, Di Mauro L, La Rocca F, Caivano A, Morano A, Frassoni F, Cilloni D, Del Vecchio L, Musto P.

Oncotarget. 2016 Feb 9;7(6):6676-92. doi: 10.18632/oncotarget.6791.

9.

Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia.

Trino S, De Luca L, Simeon V, Laurenzana I, Morano A, Caivano A, La Rocca F, Pietrantuono G, Bianchino G, Grieco V, Signorino E, Fragasso A, Bochicchio MT, Venturi C, Rosti G, Martinelli G, Del Vecchio L, Cilloni D, Musto P.

Tumour Biol. 2016 Jan;37(1):217-25. doi: 10.1007/s13277-015-3772-9.

PMID:
26194865
10.

Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH.

Rosso V, Bracco E, Pedrola R, Carturan S, Signorino E, Petiti J, Calabrese C, Nicoli P, De Gobbi M, Gaidano V, Gallo D, Ulisciani S, Fava C, Rege-Cambrin G, Frassoni F, Saglio G, Cilloni D.

Biomark Res. 2015 Jul 3;3:15. doi: 10.1186/s40364-015-0039-y.

11.

Development of cellular and humoral response against WT1 protein vaccination in mice.

Nicoli P, Calabrese C, Pellegrino RM, Rosso V, Bracco E, Signorino E, Carturan S, Petiti J, Gallo D, Gaidano V, De Gobbi M, Roetto A, Saglio G, Cilloni D.

Am J Hematol. 2015 Sep;90(9):E193-4. doi: 10.1002/ajh.24092. No abstract available.

12.

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators..

Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545.

13.

Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.

Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AA, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Voso MT, Alimena G, Fenu S, Mandelli F, Angelucci E.

BMJ Support Palliat Care. 2016 Mar;6(1):80-8. doi: 10.1136/bmjspcare-2014-000726.

PMID:
25204541
14.

Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.

Aslanyan MG, Kroeze LI, Langemeijer SM, Koorenhof-Scheele TN, Massop M, van Hoogen P, Stevens-Linders E, van de Locht LT, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt EW, de Witte T, van der Reijden BA, Suciu S, Jansen JH.

Ann Hematol. 2014 Aug;93(8):1401-12. doi: 10.1007/s00277-014-2055-7.

PMID:
24994606
15.

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators..

Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435.

16.

Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations.

Pennucci V, Zini R, Norfo R, Guglielmelli P, Bianchi E, Salati S, Sacchi G, Prudente Z, Tenedini E, Ruberti S, Paoli C, Fanelli T, Mannarelli C, Tagliafico E, Ferrari S, Vannucchi AM, Manfredini R; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators..

Leuk Lymphoma. 2015 Feb;56(2):492-6. doi: 10.3109/10428194.2014.910661. No abstract available.

PMID:
24707949
17.

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.

Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300.

PMID:
24580147
18.

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.

Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, Tenedini E, Pieri L, Paoli C, Mannarelli C, Fjerza R, Rumi E, Stalbovskaya V, Squires M, Cazzola M, Manfredini R, Harrison C, Tagliafico E, Vannucchi AM; COMFORT-II Investigators.; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators..

Blood. 2014 Apr 3;123(14):2157-60. doi: 10.1182/blood-2013-11-536557.

19.

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F Sr, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T.

J Clin Oncol. 2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571.

PMID:
24297940
20.

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

Valencia A, Masala E, Rossi A, Martino A, Sanna A, Buchi F, Canzian F, Cilloni D, Gaidano V, Voso MT, Kosmider O, Fontenay M, Gozzini A, Bosi A, Santini V.

Leukemia. 2014 Mar;28(3):621-8. doi: 10.1038/leu.2013.330.

Items per page

Supplemental Content

Loading ...
Support Center